StockData
Kyntra Bio, Inc. logo

Kyntra Bio, Inc. (KYNB) stock

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.04−1.16 (-36.25%)

Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –

Earnings

Kyntra Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 9, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
-$1.50M
-215.4% on a year earlier
EPS, Q2 FY2026
$2.96
Latest guidance
Reaffirmed
Nov 12, 2024 · 2 items

Quarterly results

Revenue and earnings per share from each of Kyntra Bio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 9, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close-$1.50M-215.4%$2.96Release
Q1 FY2026ended Mar 31, 2026May 11, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Mar 16, 2026after the close$1.30M-58.1%-$3.51Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025after the close$1.10M-97.6%–Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025after the close$1.30M-97.4%–Release
Q1 FY2025ended Mar 31, 2025May 12, 2025after the close$2.70M-95.2%$0.05Release
Q4 FY2024ended Dec 31, 2024Mar 17, 2025after the close$3.10M-88.6%-$0.08Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024after the close$46.30M+15.5%-$0.17Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$50.60M+14.2%-$0.16Release
Q1 FY2024ended Mar 31, 2024May 6, 2024after the close$55.90M+54.4%-$0.33Release
Q4 FY2023ended Dec 31, 2023Feb 26, 2024after the close$27.10M-21.2%-$0.57Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Kyntra Bio guided for has been reported

Guidance history

Every forecast Kyntra Bio put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 12, 2024expected full year roxadustat net sales in China1 by FibroGen and the JDEFY2024$330.00M – $350.00MNew
Nov 12, 2024net product revenue under U.S. GAAPFY2024$135.00M – $150.00MReaffirmed
Aug 6, 2024roxadustat net sales in ChinaFY2024$320.00M – $350.00MRaised
Aug 6, 2024net product revenueFY2024$135.00M – $150.00MRaised
May 6, 2024roxadustat net sales in ChinaFY2024$300.00M – $340.00MNew
May 6, 2024net product revenue under U.S. GAAPFY2024$120.00M – $135.00MReaffirmed
Feb 26, 2024net product revenue under U.S. GAAPFY2024$120.00M – $135.00MNew
Nov 7, 2022ending cash balanceFY2022$380.00M – $410.00MRaised
Aug 8, 2022ending cash balanceFY2022$330.00M – $360.00MRaised
May 9, 2022ending cash balanceFY2022$310.00M – $340.00MRaised
Feb 28, 2022ending cashFY2022$270.00M – $300.00MNew
Nov 9, 2021ending balance of cash, cash equivalents, investments, and accounts receivableFY2021$580.00M – $610.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Kyntra Bio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. News
  7. Results
  8. News
  9. News
  10. Results
  11. Results
  12. Update
  13. Results
  14. Results
  15. Results

See a number that looks wrong?